Worldwide perspective of biosimilars for psoriasis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|177|6|1473-1473

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.177, Iss.6, 2017-12, pp. : 1473-1473

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1495-1502

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, efficacy, and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e163-e163

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 509-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 2, 2015-02 ,pp. : 224-231

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biosimilars and haemophilia

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 17-19

John Wiley & Sons Inc

Access to resources Recommend Favorite